Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- FY2014 Medical Fee Revision Expected to Shift Outpatient Care Functions from Large Hospitals to Smaller Hospitals and Clinics, Alter Patient Behavior and Prescription Patterns
March 28, 2014
- PMDA Floats New Advisory Service on Drug Makers’ Development Plans
March 27, 2014
- PMDA Announces Increase in Face-to-Face Consultation Fees in Response to Upcoming Hike in Consumption Tax
March 27, 2014
- PMDA Publishes RMP for Regpara
March 27, 2014
- Dr Tatsuya Kondo Reappointed as Chief Executive of PMDA
March 26, 2014
- MHLW Approves 37 Products, 4 New SGLT-2 Products OK’ed
March 25, 2014
- MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
- Extra Market Drug Price Survey Focal Point of Discussions towards FY2015 Tax Hike: Official
March 20, 2014
- MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
- MHLW to Draft Rules for Approval of Switch OTC Diagnostics in Meetings Open to the Public: Regulatory Reform Council
March 19, 2014
- MHLW OKs Additional Indications for Votrient, 2 Other Drugs
March 18, 2014
- FY2014 Reform to Strengthen Restrictions on Prescription of Multiple Psychotropic Drugs; Measures to Be Taken in Two Consecutive Reforms Due to Lack of Improvements
March 18, 2014
- PMDA to Up Review Fees for Generics, OTCs, Diagnostics in November
March 17, 2014
- Rules for Approval of Switch OTC Diagnostics to Be Finalized by PAFSC Committee by End of Year: PFSB Director General
March 17, 2014
- Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
- Opposition Lawmaker Raps Favorable Treatment for Special Zones in Mixed Healthcare
March 14, 2014
- Chuikyo Approves Promotion of Mixed Healthcare in National Strategic Special Zones, Reduction of Review Period by Half
March 14, 2014
- Committee for Assessment of Advanced Healthcare Services Holds 1st Meeting to Expedite Off-label Use of Anticancer Drugs under Senshin-iryo B program
March 13, 2014
- MHLW Notifies Prefectures of Rules on Online OTC Drug Sales
March 12, 2014
- Settlements Allowing Retroactive Modifications of Transaction Price Not Regarded as Settlements under New Price Cut Rule
March 12, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…